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Abstract
Background: Development of electroanatomical systems make it possible to perform ablations without 
the use of fluoroscopy. The aim of this study was to evaluate the efficacy and safety of cryoablation pro-
cedures without the use of fluoroscopy.
Methods: The study group consisted of 45 patients (14 female; age 36 ± 15 years) treated with cry-
oablation using the EnSite electroanatomical system: 10 with ventricular extrasystoly from the right 
ventricle, 6 with the arrhythmogenic site near the left coronary artery, 17 patients with Wolff-Parkinson-
-White syndrome (WPW), 2 patients with atrioventricular nodal reentrant tachycardia (AVNRT) type 2,  
7 patients with AVNRT type 1, 3 patients with atrial tachycardia.
Results: In 38 of the 45 patients (84%) cryoablation procedure was performed without the use of 
fluoroscopy. Cryoablation efficacy was 78.9%. In 5 patients unsuccessful cryoablation was fallowed by 
radiofrequency applications. Finally, efficacy reached 92.1%. There were no deaths. In 1 patient a small 
adverse event — right bundle branch block was observed after ablation of para-Hisian accessory path-
way. No other adverse events were observed. In the long term follow-up efficacy was 89.5%.
Conclusions: Cryoablation using electroanatomical system without the use of fluoroscopy is a safe and 
efficient procedure and it is a possible alternative in most patients qualified for cryoablation. (Cardiol 
J 2018; 25, 3: 327–332)
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Introduction
Due to technological improvements in field of 
electroanatomical mapping (EAM) systems there 
is a possibility to reduce fluoroscopy. In selected 
arrhythmias fluoroless ablation is possible with the 
use of EAM system [1, 2]. Because there is no safe 
ionizing radiation dose, in 2005 Hirsfeld introduced 
a strategy of As Low As Reasonably Achievable 
(ALARA), involving the use of various techniques 
to reduce fluoroscopy [3]. This is mainly important 
in children [4], patients with an oncological history, 
and also in pregnant women [5–8]. X-rays could 
affect the structure of DNA, whereas fluoroscopy 
impairs the repair processes of DNA structure. 
Therefore, catheter ablation with the use of EAM 
(without fluoroscopy) could be safer than conven-
tional ablation [2, 9–11].
Due to technological advancements, the 
amount of catheter ablations has increased and 
procedures have become shorter. In recent years, 
it was possible to perform more complex ablations 
with a significant reduction or even without using 
fluoroscopy [4–8, 12–24]. Ablation without fluoros-
copy allows a reduced risk of delayed side effects 
from ionizing radiation. The risk assessment of 
X-ray should be performed individually before 
ablation in each patient in order to decrease the 
risk of delayed side effects. The most preferred 
method would be to perform ablation without the 
use of fluoroscopy, allowing for decreased risk of 
adverse events and increasing ablation efficacy. 
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However, thus far there is limited data about safety 
procedures performed without the use of fluoros-
copy [4–8, 12–25].
The aim of this study was to assess the fea-
sibility, safety and efficacy of cryoablation without 
the use of fluoroscopy or limited fluoroscopy time 
and dose area product in various arrhythmias with 
the help of EAM system.
Methods
The group of patients
Fourty five patients were enrolled (14 women 
[F], 31 men [M], aged 36 ± 15 years) and treated with 
cryoablation using EAM system (EnSite NavX, St. 
Jude Medical), and catheter Freezor 7 F (Medtronic). 
These patients were treated with cryoablation 
using EAM system due to prior unsuccessful ra-
diofrequency (RF) ablation (n = 16) and patients 
with arrhythmogenic sites localized near important 
anatomical and electrophysiological structures in 
the heart or with high risk of adverse events with 
the use of RF ablation (n = 29). The study had 
a positive opinion of the local bioethical committee. 
In the present group there were 10 patients 
with ventricular arrhythmias (ventricular ex-
trasystolic beats [VEBs]) of the right ventricle, 
6 patients with the site of ventricular arrhythmia 
in a region near the left coronary artery (LCA) 
ostium, disqualified from RF ablation, 17 patients 
with Wolff-Parkinson-White (WPW) syndrome 
(7 patients with para-Hisian accessory pathway, 
10 with septal accessory pathway), 2 patients with 
atrioventricular nodal tachycardia type 2 (AVNRT 
t2), 7 patients with atrioventricular nodal tachy-
cardia type 1 (AVNRT t1), 3 patients with atrial 
tachycardia (AT). In 2 patients arrhythmogenic 
sites were localized in the left ventricle therefore 
there was a need to use fluoroscopy. 17 proce-
dures were redo: 9 patients with WPW syndrome, 
6 patients with VEBs and 2 patients with AVNRT. 
In patients with WPW syndrome RF ablation was 
not performed because the location of bundle 
branch or atrioventricular node being too close. 
In patients with AVNRT ablation, proceeding was 
discontinued because of a small Koch triangle and 
registration of His potential across a large area.
The first reference group was 70 patients (38 F, 
32 M; age 44 ± 18 years) who had cryoablation 
without using EAM system: AVNRT — 32 patients, 
WPW syndrome — 19 patients, VEBs/ventricular 
tachycardia (VT) — 10 patients, typical atrial flutter 
(AFL) — 8 patients, AT — 1 patient.
The second reference group consisted of 143 
consecutive patients (79 F, 64 M; age 49 ± 19 
years) who underwent conventional RF ablation 
(without using EAM system) during the same 
period as patients in the study group: AVNRT — 
83 patients, WPW syndrome — 30 patients, AFL 
— 20 patients, AT — 2 patients, ablation of the 
atrioventricular node — 8 patients. 
The efficacy between the groups was not as-
sessed because of the different types of arrhyth-
mia in the study group and the reference groups. 
Comparison was performed only in procedural data 
(procedure and fluoroscopy duration, number and 
duration of applications) (Table 1). 
Ablation
Before ablation all patients signed an informed 
voluntary consent form. The right atrium or right 
ventricle was reached through the femoral vein. 
Left ventricle or aorta was reached through the 
femoral artery. One patient with left posterolateral 
Table 1. Procedure data in study group and in reference groups.
Study group  
(n = 38)
Reference group 1  
(n = 70)
Reference group 2  
(n = 143)
P 1 P 2
Procedure time [min] 110 ± 43 114 ± 54 80 ± 40 NS < 0.05
Application time [min] 26.6 ± 20.5 31.6 ± 34.8 8.1 ± 10.8 NS < 0.05
VEBs 15 10 0 NS < 0.05
AVNRT 6 32 83 < 0.05 < 0.05
WPW syndrome 15 19 30 NS NS
Atrial tachycardia 2 1 2 NS NS
Atrial flutter 0 8 20 NS < 0.05
Atrial fibrillation 0 0 8 NS NS
AVNRT — atrioventricular nodal reentrant tachycardia; NS — non-significant; VEB — ventricular extra beat; WPW — Wolff-Parkinson-White
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accessory pathway was catheterized via patent 
foramen ovale (PFO). 
In the study group, all catheter ablations was 
performed with the use of EAM system. EnSite 
system enables visualization of each catheter, 
which came into the vascular system outside the 
vascular sheath. It allows visualization of the veins 
and arteries which pass to the heart without the 
use of fluoroscopy (Figs. 1, 2). 
After the electrophysiological study (EPS), de-
tailed electroantomical maps of the arrhythmogenic 
sites were created. Then, cryomaping was per-
formed (application of up to –30oC for up to 60 s). 
After safe and successful cryomapping, the cryoab-
lation was performed (temperature decrease below 
–75oC during the application for at least 240 s). 
In 5 patients immediate efficacy of cryoablation was 
not achieved, therefore this method was changed 
to RF ablation. 
After ablation, antiarrhythmic drugs were 
discontinued. Duration time of the procedure was 
measured from the local anesthesia to catheter 
removal from the vessels. When fluoroscopy was 
used, time was measured in minutes with a dose 
area product in cGy/cm2. The immediate efficacy 
of the ablation procedure was assessed individu-
ally for each arrhythmia and its absence in the 
control EPS in short term follow up after ablation 
(at least 15 min after the last application). Long 
term follow-up was evaluated based on a 24-h 
electrocardiogram (ECG) Holter from 4 to 8 weeks 
after ablation. The follow-up included 6 months 
observation for each patient. Adverse events were 
divided into small and large. Small adverse events 
included: hematoma in the groin, arteriovenous 
fistula and pseudoaneurysm, bundle branch block. 
Large adverse events included: atrioventricular 
block, cardiac tamponade, death, aortic dissection, 
and mechanical damage of valves or large vessels.
Statistical analysis
Quantitative parameters were presented as 
means ± standard deviation (SD). Qualitative 
data were presented with numerical percent-
ages. Groups were compared statistically with the 
Mann-Whitney-Wilcoxon test and were statistically 
significant at p < 0.05.
Results
In 38 of 45 patients (84%) cryoablations were 
performed completely without the use of fluoros-
copy: 9 patients with VEBs of the right ventricle, 
6 patients with VEBs with site close to the ostium 
Figure 1. EnSite map of posteroseptal region of the right atrium. Series cryoapplications (red dots) near the ostium of 
coronary sinus in patient with Wolff-Parkinson-White syndrome and right posteroseptal accessory pathway.
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of LCA, 15 patients with WPW syndrome, 2 pa-
tients with AVNRT t2, 4 patients with AVNRT 
t1, 2 patients with AT and arrhythmogenic site 
close to the ostium of coronary sinus. In 8 patients 
the cryoablation was unsuccessful. Therefore, in 
5 patients additional RF ablation was performed. In 
3 patients previous RF ablation was unsuccessful: 
1 patient with wide right-sided accessory pathway, 
1 patient with VEBs from the ostium of LCA and 
1 patient with right-sided posteroseptal accessory 
pathway. Due to redo procedures additional RF 
ablation were not performed.
In 38 patients with cryoablation without the 
use of fluoroscopy overall procedure time was 
110 ± 43 min (the first reference group: 114 ± 54 
min; NS; the second reference group 80 ± 40 min; 
p < 0.05), the average application time was 26.6 ± 
± 20.5 min (the first reference group 31.6 ± 34.8 min; 
p = NS, the second reference group 8.1 ± 10.8 min, 
p < 0.05), the number of applications was 6.8 ± 5.2 
(the first reference group 5.9 ± 7.4; NS, the second 
reference group 8.9 ± 8.2; NS). 
In 19 patients the arrhythmogenic sites were 
close to important anatomical structures (13 close 
to the atrioventricular node or His bundle and 
6 close to LCA ostium).
In 7 (15.6%) patients fluoroscopy was used 
because of the difficulties in catheter navigation 
or increased risk of adverse events (fluoroscopy 
time in this group was 7.6 ± 7.2; range from 1.4 
to 34.7 min), dose area product was 722 ± 1371 
cGy/cm2. Fluoroscopy was used in 2 patients with 
left-sided accessory pathway (difficulties with 
catheter movements), 3 patients with AVNRT with 
a small Koch triangle (higher risk of atrioventricu-
lar block), 1 patient with AT and 1 patient with 
VEBs (difficulties with catheter stabilization). In 
the first reference group fluoroscopy duration was 
8.5 ± 6.9 min (NS). In the second reference group 
fluoroscopy time was 10.6 ± 8.1 min (p < 0.05). 
In the first reference group dose area product was 
1366.6 ± 1302.7 cGy/cm2 (p < 0.05), in the second 
647.2 ± 938.4 cGy/cm2 (NS). 
Immediate efficacy of cryoablation without use 
of fluoroscopy was 78.9% (30/38). After consider-
ing an additional method of RF ablation efficacy 
increased to 92.1% (35/38). In long term follow 
up efficacy was 89.5% (34/38). In the study group 
(patients with the use of fluoroscopy and without 
fluoroscopy) efficacy was 88.9% (40/45) in long 
term follow up. In 1 patient there was a small 
adverse event — right bundle branch block was 
Figure 2. EnSite map of Koch triangle in patient with atrioventricular nodal reentrant tachycardia. Green catheter in 
the coronary sinus, white ablation catheter. Blue dots indicate site of His bundle. Brown dot indicates the place of 
successful cryoablation.
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observed after ablation of para-Hisian accessory 
pathway. No other adverse events were observed.
Discussion
Radiation exposure related to conventional 
catheter ablation which carries a small but not 
negligible stochastic and deterministic effects on 
health. These effects are cumulative and poten-
tially more harmful in younger individuals. EAM 
systems can significantly reduce the radiological 
exposure and in some cases it can completely 
eliminate it. This is especially important in preg-
nant women, patients with oncological history or 
diseases of the hematologic system. To date there 
are few reports on fluoroless ablation in pregnant 
women [5–7].
Ablation procedures for arrhythmias have in-
creased in frequency and complexity over the last 
decade. RF ablation is still the prefered method of 
catheter ablation. However, in selected patients 
the cryoablation is safer and could be a method of 
choice, mainly in patients with high risk of dam-
age of important anatomic and electrophysiologic 
structures in the heart during RF procedure. 
Initially, EAM system allows a reduction in 
fluoroscopic time and dose area product [12–16, 26, 
27]. In a NO PARTY multicenter randomized study 
which presented the use of EAM system (EnSite) 
to a significant reduction fluoroscopy time and dose 
area product in supraventricular tachycardia (SVT) 
compared to the conventional ablation treatment 
[13]. Subsequent to this, there were reports of RF 
ablation procedures performed entirely without the 
use of fluoroscopy in SVT [5, 6, 8, 17–22]. Casella 
et al. [13] shows that RF ablation without the use of 
fluoroscopy in 38 patients with supraventricular ar-
rhythmias (AFL, WPW syndrome, AVNRT and AT) 
is safe and successful. In multicenter prospective 
registry Stec et al. [21] presented that 179 of 188 
procedures were done without fluoroscopy with 
a success rate of 98% and no major complications. 
Koźluk et al. [22] presented safety and efficacy 
of fluoroless ablation in the left ventricle of a patient 
with benign and malignant VTs [6]. The most diffi-
cult ablation to do without fluoroscopy is pulmonary 
vein isolation [22]. Use of EAM system allows 
a significant reduction of this disadvantage [26, 27], 
the treatment, however, without fluoroscopy is 
only possible if PFO is present [23]. Bulava et al. 
[24] introduced transseptal puncture only under in-
tracardiac echocontrol. In combination with EAM, 
this allows most patients to perform PVI without 
fluoroscopy [24]. In the study presented herein, 
we demonstrates the feasibility of performing safe 
and successful fluoroless cryoablation for various 
arrhythmias.
In a meta-analysis, Yang et al. [25] presented, 
that procedure duration with zero or near-zero fluoro-
scopy was not significantly different from that of 
conventional ablation. There were also no significant 
differences between both groups in success rate (direct 
and long-term), complications or recurrence rates.
The main advantage of cryoablation is its long 
reversibility (1 min), this makes it safe compared 
to RF ablation in patients with arrhythmogenic 
sites close to electrophysiological structures like 
atrioventricular node or His bundle. Advances in 
EAM systems have allowed flouroless cryoablation 
in various arrhythmias including redo procedures 
and various localization of arrhythmogenic sites. 
Conclusions
1. In 38 of 45 patients (84.4%) cryoablation was 
performed without the use of fluoroscopy. 
2. There were no significant complications in the 
study group.
3. Immediate cryoablation efficacy was 78.9% 
(with additional RF applications — 92.1%), 
and in long term follow up — 89.5%.
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